ch.oddb.org
 
Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Dostinex®:Pfizer PFE Switzerland GmbH
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Zusammens.Galen.FormInd./Anw.mögl.Dos./Anw.Kontraind.Warn.hinw.Interakt.Schwangerschaft
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
G02CB03 - CabergolineATC-DDD Version 2016. Source: WHO
G - Genito Urinary System and Sex Hormones
 
G02 - Other Gynecologicals

Analgesics used in dysmenorrhea, see N02B - Other analgesics and antipyretics and M01A - Antiinflammatory and antirheumatic products, non-steroids.

G02C - Other Gynecologicals
 
G02CB - Prolactine Inhibitors

Cabergoline and bromocriptine low dose tablets are classified in this group. Cabergoline and bromocriptine tablets in higher strengths are classified in N04 - Anti-Parkinson drugs.
Lisuride tablets in high strength (0.2 mg) are classified in this group, while low strength tablets (25 mcg) are classified in N02C -Antimigraine preparations.

The DDDs are based on use as lactation inhibitors. The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.

G02CB03 - Cabergoline
StärkeAdm.RouteNote
0.5 mgO 
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home